These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36750040)

  • 1. Circulating Glypican-4 Is a Predictor of 24-Month Overall Survival in Metastatic Breast Cancer.
    Muendlein A; Heinzle C; Brandtner EM; Leiherer A; Drexel H; Dechow T; Decker T
    Oncol Res Treat; 2023; 46(4):151-156. PubMed ID: 36750040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients.
    Muendlein A; Severgnini L; Decker T; Heinzle C; Leiherer A; Geiger K; Drexel H; Winder T; Reimann P; Mayer F; Nonnenbroich C; Dechow T
    Front Oncol; 2022; 12():1045995. PubMed ID: 36353562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating glypican-4 is a new predictor of all-cause mortality in patients with heart failure.
    Muendlein A; Heinzle C; Leiherer A; Brandtner EM; Geiger K; Gaenger S; Fraunberger P; Mader A; Saely CH; Drexel H
    Clin Biochem; 2023 Nov; 121-122():110675. PubMed ID: 37844682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum glypican-4 is associated with the 10-year clinical outcome of patients with peripheral artery disease.
    Muendlein A; Heinzle C; Leiherer A; Geiger K; Brandtner EM; Gaenger S; Fraunberger P; Saely CH; Drexel H
    Int J Cardiol; 2022 Dec; 369():54-59. PubMed ID: 35944770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum glypican-4 is a marker of future vascular risk and mortality in coronary angiography patients.
    Muendlein A; Brandtner EM; Leiherer A; Geiger K; Heinzle C; Gaenger S; Fraunberger P; Mader A; Saely CH; Drexel H
    Atherosclerosis; 2022 Mar; 345():33-38. PubMed ID: 35202959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma apolipoprotein M predicts overall survival in metastatic breast cancer patients.
    Muendlein A; Heinzle C; Brandtner EM; Leiherer A; Geiger K; Gaenger S; Drexel H; Dechow T; Decker T
    Breast Cancer Res Treat; 2023 Oct; 201(3):571-576. PubMed ID: 37490173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
    Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
    JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
    Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
    JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.
    Cabel L; Rosenblum D; Lerebours F; Brain E; Loirat D; Bergqvist M; Cottu P; Donnadieu A; Bethune A; Kiavue N; Rodrigues M; Pierga JY; Tanguy ML; Bidard FC
    Breast Cancer Res; 2020 Sep; 22(1):98. PubMed ID: 32928264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dichotomous Effects of Glypican-4 on Cancer Progression and Its Crosstalk with Oncogenes.
    Chérouvrier Hansson V; Cheng F; Georgolopoulos G; Mani K
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
    Yang X; Rao J; Yang W; Shui R
    Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GPC4, the gene for human K-glypican, flanks GPC3 on xq26: deletion of the GPC3-GPC4 gene cluster in one family with Simpson-Golabi-Behmel syndrome.
    Veugelers M; Vermeesch J; Watanabe K; Yamaguchi Y; Marynen P; David G
    Genomics; 1998 Oct; 53(1):1-11. PubMed ID: 9787072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the association of serum glypican-4 with prevalent and future kidney function.
    Muendlein A; Brandtner EM; Leiherer A; Geiger K; Heinzle C; Gaenger S; Fraunberger P; Haider D; Saely CH; Drexel H
    Sci Rep; 2022 Jun; 12(1):10168. PubMed ID: 35715556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.
    Rozenblit M; Mun S; Soulos P; Adelson K; Pusztai L; Mougalian S
    Breast Cancer Res; 2021 Jan; 23(1):14. PubMed ID: 33514405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer.
    Zhou J; Wu X; Zhang H; Wang X; Yuan Y; Zhang S; Jiang Z; Wang T
    Breast; 2022 Dec; 66():255-261. PubMed ID: 36375386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
    Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
    Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of the glypican family of heparan sulfate proteoglycans on the survival of breast cancer patients.
    Grillo PK; Győrffy B; Götte M
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):1937-1955. PubMed ID: 33742285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
    Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.